Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

(2014) Talmadge E. King et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C

(2013) Nicola Coppola et al.   Clinical Gastroenterology and Hepatology

Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C

(2011) Bryce S Foote et al.   ANNALS OF PHARMACOTHERAPY

Pirfenidone for Diabetic Nephropathy

(2011) K. Sharma et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Telaprevir for Retreatment of HCV Infection

(2011) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Splanchnic Balance of Free Fatty Acids, Endocannabinoids, and Lipids in Subjects With Nonalcoholic Fatty Liver Disease

(2010) Jukka Westerbacka et al.   GASTROENTEROLOGY

Endocannabinoids in liver disease

(2010) Joseph Tam et al.   HEPATOLOGY

Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in hepatocytes

(2010) Andrea De Gottardi et al.   LIVER INTERNATIONAL

Potent antioxidant role of Pirfenidone in experimental cirrhosis

(2008) Adriana Salazar-Montes et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Protective effects of pirfenidone on D-galactosamine and lipopolysaccharide-induced acute hepatotoxicity in rats

(2008) F. Wang et al.   INFLAMMATION RESEARCH

Endocannabinoids and Liver Disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis

(2007) Sören V. Siegmund et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Endocannabinoids and Liver Disease. I. Endocannabinoids and their receptors in the liver

(2007) A. Mallat et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY